NAMS

NewAmsterdam Pharma Company N.V. NASDAQ Listed Feb 9, 2021

Healthcare ·Biotechnology ·NL · newamsterdampharma.com

$30.99

After hrs $31.22 +0.74%

Mkt Cap $3.6B

52w Low $16.79 56.3% of range 52w High $42.00

50d MA $31.68 200d MA $31.77

P/E (TTM) -16.2x

EV/EBITDA -14.5x

P/B 4.8x

Debt/Equity 0.0x

ROE -29.8%

P/FCF -27.1x

RSI (14) —

ATR (14) —

Beta 0.13

50d MA $31.68

200d MA $31.77

Avg Volume 855.8K

About

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same tim…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 18, 2026	AMC	-0.40	-0.63	-57.5%	35.76	-0.6%	-3.2%	-0.5%	+1.1%	+0.7%	-2.1%	—
Nov 5, 2025	AMC	-0.38	-0.41	-7.9%	38.13	+0.7%	-2.8%	-3.6%	+2.2%	+4.6%	+0.5%	—
Aug 6, 2025	AMC	-0.52	-0.15	+71.2%	23.62	+0.5%	-2.8%	+7.2%	+3.2%	+5.8%	+9.1%	—
May 8, 2025	AMC	-0.45	-0.49	-8.9%	19.27	+0.1%	-4.7%	-0.3%	-2.7%	-2.7%	-3.0%	—
Feb 26, 2025	AMC	-0.48	-0.95	-97.9%	19.71	+1.5%	+6.1%	+6.5%	+2.8%	+9.1%	+16.8%	—
Nov 6, 2024	AMC	-0.48	-0.18	+62.5%	21.78	+0.8%	+3.9%	+10.7%	+12.9%	+13.7%	+12.9%	—
Aug 7, 2024	AMC	-0.59	-0.51	+13.6%	15.66	+1.4%	+8.0%	+11.0%	+8.8%	+10.0%	+8.6%	—
May 8, 2024	AMC	-0.54	-0.62	-14.8%	21.79	-1.3%	+0.3%	-1.7%	-7.3%	-5.9%	-9.1%	—
Mar 29, 2024	AMC	-0.60	-0.57	+5.5%	—	—	—	—	—	—	—	—
Feb 28, 2024	AMC	-0.55	-0.54	+1.8%	23.62	+5.8%	-3.3%	-0.3%	-2.4%	-5.7%	-6.7%	—
Aug 7, 2023	AMC	-0.39	-0.47	-19.9%	10.71	-1.5%	+0.0%	-0.1%	+3.5%	+1.7%	-0.1%	—
Jun 30, 2023	AMC	-0.44	-0.52	-17.2%	11.89	+1.1%	+0.9%	-0.3%	-0.8%	-0.6%	+1.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 19	Guggenheim	Maintains	Buy → Buy	—	$35.76	$35.56	-0.6%	-3.2%	-0.5%	+1.1%	+0.7%	-2.1%
Feb 18	Needham	Maintains	Buy → Buy	—	$35.24	$35.29	+0.1%	+1.5%	-1.7%	+1.0%	+2.6%	+2.2%
Jan 21	RBC Capital	Maintains	Outperform → Outperform	—	$32.41	$32.60	+0.6%	+4.7%	+7.4%	+2.8%	-0.1%	+0.7%
Dec 16	Stifel	Maintains	Buy → Buy	—	$35.35	$35.29	-0.2%	-3.2%	-4.7%	-4.1%	-0.7%	+3.2%
Dec 2	Goldman Sachs	Maintains	Neutral → Neutral	—	$39.61	$39.60	-0.0%	-3.2%	-10.3%	-9.5%	-11.0%	-9.7%
Nov 6	RBC Capital	Maintains	Outperform → Outperform	—	$38.13	$38.38	+0.7%	-2.8%	-3.6%	+2.2%	+4.6%	+0.5%
Nov 5	Needham	Maintains	Buy → Buy	—	$36.53	$35.42	-3.0%	+4.4%	+1.4%	+0.6%	+6.7%	+9.2%
Oct 17	Citigroup	Maintains	Buy → Buy	—	$36.47	$36.02	-1.2%	-0.2%	+3.3%	+0.0%	-4.0%	-0.5%
Aug 7	RBC Capital	Maintains	Outperform → Outperform	—	$23.62	$23.73	+0.5%	-2.8%	+7.2%	+3.2%	+5.8%	+9.1%
Jun 12	Needham	Maintains	Buy → Buy	—	$20.50	$20.42	-0.4%	+2.6%	-1.4%	-3.7%	-9.8%	-11.2%
May 8	Needham	Maintains	Buy → Buy	—	$18.92	$18.92	+0.0%	+1.8%	-2.9%	+1.6%	-0.9%	-0.9%
Apr 8	Needham	Maintains	Buy → Buy	—	$15.86	$16.32	+2.9%	-4.4%	+0.0%	-6.1%	-4.7%	+3.5%
Feb 27	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$19.71	$20.01	+1.5%	+6.1%	+6.5%	+2.8%	+9.1%	+16.8%
Feb 27	Needham	Maintains	Buy → Buy	—	$19.71	$20.01	+1.5%	+6.1%	+6.5%	+2.8%	+9.1%	+16.8%
Jan 28	RBC Capital	Maintains	Outperform → Outperform	—	$22.61	$22.14	-2.1%	-5.1%	-8.1%	-3.7%	-1.4%	-5.5%
Jan 24	RBC Capital	Maintains	Outperform → Outperform	—	$23.20	$23.20	+0.0%	+1.7%	-2.5%	-7.5%	-10.4%	-6.2%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.58	$24.68	+0.4%	-3.7%	-2.4%	-4.7%	-4.2%	-3.6%
Dec 11	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$26.19	$26.90	+2.7%	-2.4%	-4.2%	-5.7%	-5.7%	+1.6%
Dec 5	Needham	Maintains	Buy → Buy	—	$18.27	$17.96	-1.7%	-1.1%	+0.4%	+1.4%	+43.3%	+40.0%
Nov 21	Needham	Maintains	Buy → Buy	—	$20.01	$20.22	+1.0%	+0.5%	+0.9%	+5.2%	+4.1%	+3.9%
Nov 11	Needham	Maintains	Buy → Buy	—	$24.12	$24.18	+0.2%	+1.9%	+2.7%	+2.0%	+3.5%	+3.2%
Nov 7	Needham	Maintains	Buy → Buy	—	$21.78	$21.96	+0.8%	+3.9%	+10.7%	+12.9%	+13.7%	+12.9%
Sep 23	Piper Sandler	Maintains	Overweight → Overweight	—	$15.92	$16.09	+1.1%	-2.8%	-2.3%	-4.3%	-0.6%	+1.9%
Sep 5	RBC Capital	Maintains	Outperform → Outperform	—	$16.02	$15.95	-0.4%	+1.1%	+2.4%	+5.4%	+2.8%	+0.9%
Jul 30	RBC Capital	Maintains	Outperform → Outperform	—	$17.25	$17.56	+1.8%	-6.2%	-0.8%	+0.1%	-1.3%	-7.6%
Jun 7	RBC Capital	Maintains	Outperform → Outperform	—	$19.60	$19.52	-0.4%	-1.5%	+0.4%	+1.3%	+1.0%	-0.8%
Mar 14	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$22.30	$22.35	+0.2%	-1.7%	-1.2%	-1.2%	-1.1%	-0.7%
Feb 29	RBC Capital	Maintains	Outperform → Outperform	—	$23.62	$24.99	+5.8%	-3.3%	-0.3%	-2.4%	-5.7%	-6.7%
Apr 3	Credit Suisse	Maintains	Outperform → Outperform	—	$13.26	$13.48	+1.7%	+2.0%	+2.0%	+1.6%	+2.3%	+1.5%

Recent Filings

8-K · 5.02 !!! Very High

NewAmsterdam Pharma Company N.V. -- 8-K 5.02: Executive Change

NewAmsterdam Pharma Company N.V. (NAMS) separated from executive Kooij, potentially signaling leadership transition that investors should monitor for strategic direction changes and impact on pipeline development.

Apr 24

8-K · 7.01 ! Medium

NewAmsterdam Pharma Company N.V. -- 8-K 7.01: Regulation FD Disclosure

NewAmsterdam Pharma (NAMS) disclosed a corporate investor presentation on March 2, 2026, providing stakeholders with updated company information and strategic messaging.

Mar 2

8-K

NewAmsterdam Pharma Company N.V. -- 8-K Filing

NewAmsterdam Pharma achieved a key regulatory milestone as the European Medicines Agency accepted marketing applications for obicetrapib and its fixed-dose combination, advancing the cardiometabolic therapy toward potential European approval.

Feb 18

Data updated apr 26, 2026 2:13pm · Source: massive.com